OPA1 and lung adenocarcinoma: To understand whether the observed Opa1 upregulation in these gefitinib-resistant lung adenocarcinoma cells was indicative of a clinically relevant condition, we investigated publicly available databases and bioinformatically evaluated whether a “mitochondria-shaping proteins” signature existed in chemoresistant lung adenocarcinoma (LUAD) patients.